The changing landscape of biosimilars in rheumatology
Top Cited Papers
Open Access
- 8 March 2016
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 75 (6), 974-982
- https://doi.org/10.1136/annrheumdis-2016-209166
Abstract
Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and health-economic potential offered by these agents. Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble receptors. Biosimilars offer cost savings and health gains for our patients and will play an important role in treating rheumatic diseases. We hope that these lower costs will compensate for inequities in access to therapy based on economic differences across countries. Since approved biosimilars have already demonstrated highly similar efficacy, it will be most important to establish pharmacovigilance databases across countries that are adequate to monitor long-term safety after marketing approval.Keywords
Funding Information
- F. Hoffman-La Roche
This publication has 57 references indexed in Scilit:
- Clinical experience with Zarzio® in Europe: what have we learned?Supportive Care in Cancer, 2013
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals Of The Rheumatic Diseases, 2013
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals Of The Rheumatic Diseases, 2013
- Does Value Mean Quality? The Payer's PerspectiveJournal of Oncology Practice, 2013
- A European perspective on the market accessibility of biosimilarsBiosimilars, 2012
- The safety of switching between therapeutic proteinsExpert Opinion on Biological Therapy, 2012
- The economic pressures for biosimilar drug use in cancer medicineTargeted Oncology, 2012
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal Of Cancer, 2010
- Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA databaseAnnals Of The Rheumatic Diseases, 2009
- Incorporating considerations of resources use into grading recommendationsBMJ, 2008